SNY Today - Aug 07: Dupixent Ads Under Fire

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

SNY Today - Aug 07: Dupixent Ads Under Fire

無料で聴く

ポッドキャストの詳細を見る

Hey there! I’m Joey, your go-to guy for stock talk, and I’ve been investing for a while now. Today, we’re chatting about Sanofi, or SNY as the cool kids call it. It was a green day for them, up about 1.85%. Not too shabby!

So what went down? Well, the stock was on the rise, but it wasn’t all smooth sailing. There’s been some noise around Dupixent, one of their big drugs. The National Advertising Division asked Sanofi to change some of their ads after a challenge from Galderma. Yeah, that one stung a bit. When your advertising gets called out, it can shake up investor confidence.

Now, why did we see this bump despite the ad drama? It looks like some investors might be feeling optimistic about Sanofi's pipeline, especially with news that Novavax is doing well thanks to their partnership. That’s always a good sign when your collabs are on point. Plus, there’s chatter about Sanofi being undervalued, which can get folks excited to buy in. But then again, we also heard about Antipodes exiting their position after some pipeline setbacks. So, it’s a bit of a mixed bag.

On the horizon, Sanofi India just reported a solid 7.73% rise in net sales for June. That’s a nice little boost and might help ease some worries around the company’s overall performance.

So, to wrap it up, SNY had a decent day, but there’s definitely some ups and downs to keep an eye on. As always, remember I’m just here sharing the info, not giving out financial advice. Catch you later!

まだレビューはありません